R&D channel feed – Endpoints News

R&D channel feed

Women are gaining more board seats in biotech, but real change is happening at a snail's pace

9 years ago

An upstart immunotherapy biotech emerges from stealth mode with big love for Kendall Square

9 years ago

Struggling Marinus gets a bump out of a positive PhII snapshot

9 years ago

Deep in talks with J&J, Actelion’s flagship drug cruises past a pivotal trial failure

9 years ago

Ovid adds $26M to its coffers as Takeda deal closes, building a war chest for pipeline construction work

9 years ago

Bristol-Myers staggered by a stunning checkpoint setback, hands Merck a free pass on frontline lung cancer combo

9 years ago

Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug

9 years ago

Dermira sweeps PhIII psoriasis studies for Cimzia as rivals threaten another entry

9 years ago

Novartis chief Jimenez touts two top PhIII drug prospects

9 years ago

Neurocrine execs shrug off a PhII setback for Tourette syndrome

9 years ago

Lagging further behind, AstraZeneca adds fresh details to its checkpoint comeback strategy

9 years ago

Alcobra blasted by a PhIII flop for ADHD drug as its options dwindle

9 years ago

Allergan aces another promising PhIII on uterine fibroid therapy, with plans to hustle the bundle to the FDA

9 years ago

Armed with $137M fund, Signet launches hunt for a dozen new biotech plays

9 years ago

Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk

9 years ago

Investigators signal thumbs-up for antibiotic, prep an FDA pitch for OK

9 years ago

Failed Nivalis pares down to a skeleton crew as it launches a salvage operation

9 years ago

CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns

9 years ago

Daiichi Sankyo launches global R&D restructuring, looking to slash costs in an overhaul

9 years ago

In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer

9 years ago

Struggling Sarepta bounces back as analysts cheer the first trickle of revenue for DMD drug

9 years ago

Biogen CEO Michel Vounatsos regroups and stakes out a BD plan for 2017

9 years ago

Secretive? Moderna details its pipeline strategy at JPM but at least one critic bites back

9 years ago

Kite lines up a JV in China while Daiichi Sankyo strikes $250M-plus deal to launch CAR-T drug in Japan

9 years ago

First page Previous page 307 308 309310311 312 313 Next page Last page